About Critical Diagnostics
Critical Diagnostics is a company that focuses on the discovery, development, and commercialization of novel biomarkers in cardiovascular diseases. Critical Diagnostics was founded in 2004. The Company licensed intellectual property discovered in 2002 at Brigham and Women’s Hospital relating to ST2, for which it now holds the exclusive worldwide rights. The company has since expanded its intellectual property portfolio and holds several issued patents in the US and abroad as well as numerous patents pending.